I-Mab (IMAB) Financial Analysis & Valuation | Quarter Chart
I-Mab (IMAB)
IMABPrice: $3.24
Fair Value: 🔒
🔒score
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human grow... more
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics... more
Description
Shares
| Market Cap | $265.11M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | CN | CEO | Xi-Yong Fu |
| IPO Date | 2020-01-17 | CAGR | — |
| Employees | 32 | Website | www.i-mabbiopharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
IMAB chart loading...
Fundamentals
Technicals
| Enterprise Value | $-77.95M | P/E Ratio | -6.35 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 0.01 |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | $-0.51 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -100% | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.19% | ROA | -0.18% |
| ROCE | -0.19% | Current Ratio | 22.82 |
| Quick Ratio | 22.82 | Cash Ratio | 22.51 |
| Debt/Equity | 0.02 | Interest Coverage | — |
| Altman Z Score | 7.42 | Piotroski Score | 3 |